Article
Multidisciplinary Sciences
Johnathan D. Guest, Ruixue Wang, Khadija H. Elkholy, Andrezza Chagas, Kinlin L. Chao, Thomas E. Cleveland, Young Chang Kim, Zhen-Yong Keck, Alexander Marin, Abdul S. Yunus, Roy A. Mariuzza, Alexander K. Andrianov, Eric A. Toth, Steven K. H. Foung, Brian G. Pierce, Thomas R. Fuerst
Summary: The variability of HCV poses a challenge for vaccine development, but a soluble form of E1E2 has been designed to elicit neutralizing antibodies in vivo and potentially optimize E1E2-based antigen production for future studies.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biophysics
Ru Cheng, Fu Zhu, Min Huang, Qiang Zhang, Hui Hong Yan, Xiao Hui Zhao, Fu Kang Luo, Chun Mei Li, Hui Liu, Gao Lin Liang, Cheng Zhi Huang, Jian Wang
Summary: In this study, a new biosensor named hepatitis virus indicator was developed for the simultaneous detection of HBV and HCV. The biosensor utilized Exo III assisted signal amplification strategy and particle counting technology with a dark-field microscopy, enabling sensitive and selective detection.
BIOSENSORS & BIOELECTRONICS
(2022)
Article
Biotechnology & Applied Microbiology
Emmeline L. Blanchard, Daryll Vanover, Swapnil Subhash Bawage, Pooja Munnilal Tiwari, Laura Rotolo, Jared Beyersdorf, Hannah E. Peck, Nicholas C. Bruno, Robert Hincapie, Frank Michel, Jackelyn Murray, Heena Sadhwani, Bob Vanderheyden, M. G. Finn, Margo A. Brinton, Eric R. Lafontaine, Robert J. Hogan, Chiara Zurla, Philip J. Santangelo
Summary: Cas13a delivered to the lung of mice and hamsters inhibits replication of influenza virus and SARS-CoV-2, suggesting that Cas13a-mediated targeting of pathogenic viruses can mitigate respiratory infections. The study successfully reduced viral RNA levels in the lung tissue of animals, demonstrating the efficacy of Cas13a in targeting RNA viruses.
NATURE BIOTECHNOLOGY
(2021)
Review
Gastroenterology & Hepatology
Alessandra Mangia, Rosa Cotugno, Giovanna Cocomazzi, Maria Maddalena Squillante, Valeria Piazzolla
Summary: The World Health Organization's goal of eliminating Hepatitis C virus (HCV) by 2030 using direct-acting antiviral treatments has become less attainable post the 2020 pandemic of coronavirus disease 2019. Therefore, a more realistic approach of micro-elimination in population segments where targeted strategies of prevention and treatment are easily attained has been promoted in Europe. Active involvement of stakeholders and community participation are essential components for the success of a micro-elimination project tailored at the geographical level according to HCV epidemiology and individual country's income.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Po-Yao Hsu, Yu-Ju Wei, Po-Cheng Liang, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ching- Huang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Ming-Lun Yeh, Chung-Feng Huang, Yi-Wen Chiu, Shang-Jyh Hwang, Wan-Long Chuang, Ming-Lung Yu
Summary: Hemodialysis patients are at increased risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. This study found that hemodialysis patients with HCV exhibited a higher burden of comorbidities, especially in ischemic heart diseases, respiratory disorders, and mental/behavioral disorders, compared to patients with HBV and those without viral hepatitis.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Editorial Material
Virology
Syeda Kanza Kazmi, Fatima Muhammad Asad Khan, Valentino Natoli, Reem Hunain, Zarmina Islam, Ana Carla dos Santos Costa, Shoaib Ahmad, Mohammad Yasir Essar
Summary: Hepatitis is a significant cause of mortality worldwide, with around 1.34 million deaths annually. Africa is not immune to this issue, with an estimated 100 million individuals infected with Hepatitis B or C. The continent, already fragile, is further burdened by the onset of the COVID-19 pandemic, which could potentially worsen the threat from viral diseases like Hepatitis. Strengthening prevention policies is essential for Africa to build resilience against such threats.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zhongyao Qian, Chenchen Yang, Liangheng Xu, Houfack K. Mickael, Shuangfeng Chen, Yike Zhang, Yueping Xia, Tengyuan Li, Wenhai Yu, Fen Huang
Summary: Hepatitis E virus-encoded miRNA (HEV-miR-A6) activates SIRP-alpha to promote viral replication by inhibiting the expression of type I interferon beta (IFN-beta).
Article
Microbiology
Chao Liang, Qianhui Xia, Jingming Zhou, Hongliang Liu, Yumei Chen, Yankai Liu, Peiyang Ding, Yanhua Qi, Aiping Wang
Summary: This study identified immunodominant CD8+ CTL epitopes for PRRSV-2 M protein and predicted their binding to SLA I molecules through a combination of ELISPOT assays and SLA genotyping. In vitro assays confirmed the formation of immune complexes between specific peptides and SLA class I molecules. These potential CTL epitopes represent a promising avenue for further research into T cell-based vaccine development for PRRSV.
VETERINARY MICROBIOLOGY
(2021)
Article
Oncology
Shih-Han Hung, Tzong-Hann Yang, Yen-Fu Cheng, Chin-Shyan Chen, Herng-Ching Lin
Summary: This case-control study investigates the associations between head and neck cancer (HNC), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, and suggests a potential association between HBV and HCV infections and the risk of HNC.
Article
Genetics & Heredity
Giovanni Mazzocco, Iga Niemiec, Alexander Myronov, Piotr Skoczylas, Jan Kaczmarczyk, Anna Sanecka-Duin, Katarzyna Gruba, Paulina Krol, Michal Drwal, Marian Szczepanik, Krzysztof Pyrc, Piotr Stepniak
Summary: The COVID-19 pandemic has led to a race towards the development of therapies and preventive strategies, with antibodies and vaccines being particularly attractive due to their specificity, low drug-drug interaction risk, and potential long-lasting protective effects. However, the implementation of these strategies should consider safety concerns, as potential adverse events like ADE and CSS have been reported. Depletion of T-cells in COVID-19 patients is associated with poor prognosis, suggesting a role for vaccines inducing cellular immunity to mitigate the risks of ADE and CSS.
FRONTIERS IN GENETICS
(2021)
Review
Immunology
Wen Hou, Xiaoli Wu
Summary: This study investigates the roles of gamma delta T cells in HBV and HCV infections, discussing the different roles they play in the progression of liver diseases at various stages.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Yandan Wu, Yan Ding, Chuanlai Shen
Summary: Hepatitis B virus infection is a global health issue with no eradicative therapy available. The lack of validated T cell epitopes hampers the development of vaccines and T cell therapies, with most epitopes restricted to common HLA supertypes. More research is needed to map a comprehensive repertoire of T cell epitopes covering the HBV proteome and global populations.
Review
Public, Environmental & Occupational Health
S. Mehmandoost, M. Khezri, G. Mousavian, F. Tavakoli, F. Mehrabi, H. Sharifi, K. Dolan, M. Shokoohi
Summary: This study systematically summarized the prevalence of HIV, HBV, and HCV infections among incarcerated people in Iran. The results showed that the prevalences of these infections are relatively high in this population. Meta-analysis and regression analysis found a decrease in HIV and HCV infections over time.
Article
Immunology
Jordan J. Feld, Julie Bruneau, Gregory J. Dore, Marc G. Ghany, Bettina Hansen, Mark Sulkowski, David L. Thomas
Summary: The design of a clinical trial for a controlled human infection model (CHIM) to accelerate hepatitis C virus (HCV) vaccine development requires careful consideration. The design of a potential approach to HCV CHIM is outlined, involving initial sentinel cohorts to establish the safety and curability of the viral inoculum followed by larger cohorts to establish the spontaneous clearance rate for each inoculum. Additional considerations are discussed, including the populations to be enrolled, the required monitoring approach, indications for antiviral therapy, and the required sample size for different CHIM approaches. Finally, safety considerations for CHIM participants are discussed.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Microbiology
Christelle Granier, Johan Toesca, Chloe Mialon, Maureen Ritter, Natalia Freitas, Bertrand Boson, Eve-Isabelle Pecheur, Francois-Loic Cosset, Solene Denolly
Summary: Hepatitis C virus (HCV) particles are stable when secreted from cells, but become highly unstable after freeze-thawing of producer cells. Cell-secreted proteins can protect HCV particles from degradation, specifically those that are lipidated and low-density. HCV particles are sensitive to oxidation, but can be protected from lipid oxidation by secreted factors.
Article
Immunology
Damien C. Tully, Judith A. Hahn, David J. Bean, Jennifer L. Evans, Meghan D. Morris, Kimberly Page, Todd M. Allen
Summary: Deep sequencing of hepatitis C virus (HCV) among self-described injecting partnerships showed that the majority of transmission events originate from outside of the injecting partnership, and the direction of transmission is often difficult to accurately infer, especially in high-risk networks with rapid transmission events.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Marta Calvet-Mirabent, Daniel T. Claiborne, Maud Deruaz, Serah Tanno, Carla Serra, Cristina Delgado-Arevalo, Ildefonso Sanchez-Cerrillo, Ignacio de Los Santos, Jesus Sanz, Lucio Garcia-Fraile, Francisco Sanchez-Madrid, Arantzazu Alfranca, Maria Angeles Munoz-Fernandez, Todd M. Allen, Maria J. Buzon, Alejandro Balazs, Vladimir Vrbanac, Enrique Martin-Gayo
Summary: The combination of 2‘3’-c ' diAM(PS)2 and Poly I:C as adjuvants can enhance DCs' ability to induce polyfunctional HIV-1 specific CD8(+) T-cell responses, reducing the severity of CD4(+) T-cell depletion following HIV-1 infection, and preserving the specific polyfunctional responses of CD8(+) T cells. The priming of DCs with PolyI:C and STING agonists may be useful for future HIV-1 vaccine studies.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Letter
Allergy
Eva Pescosolido, Yannick D. Muller, Marina Sabate-Bresco, Marta Ferrer, Daniel Yerly, Jean-Christoph Caubet, Jean-Pierre Lantin, Camillo Ribi, Marcel M. Bergmann
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Article
Substance Abuse
Richard A. Jenkins, Bridget M. Whitney, Robin M. Nance, Todd M. Allen, Hannah L. F. Cooper, Judith Feinberg, Rob Fredericksen, Peter D. Friedmann, Vivian F. Go, Wiley D. Jenkins, P. Todd Korthuis, William C. Miller, Mai T. Pho, Abby E. Rudolph, David W. Seal, Gordon S. Smith, Thomas J. Stopka, Ryan P. Westergaard, April M. Young, William A. Zule, Joseph A. C. Delaney, Judith Tsui, Heidi M. Crane
Summary: This article characterizes the opioid crisis in rural areas and introduces a project called Rural Opioid Initiative (ROI) which aims to collect and analyze data to better understand drug use in rural regions and develop tailored interventions to address the issues.
ADDICTION SCIENCE & CLINICAL PRACTICE
(2022)
Article
Allergy
Werner J. Pichler, Marie-Charlotte Brueggen
Summary: Virus infections can enhance drug hypersensitivity reactions by inducing immune stimulation and increasing the interaction with immune receptors. In some cases, severe drug hypersensitivity reactions may precede the reactivation of herpes viruses. This phenomenon can be explained by the immune stimulation during drug reactions, which activates herpes-specific T cells and leads to the release of herpes viruses. These concepts explain the transient nature of drug hypersensitivity reactions during viral infections and the asymptomatic herpes-virus viremia after severe drug hypersensitivity reactions.
Article
Biochemistry & Molecular Biology
Lucia Bailon, Anuska Llano, Samandhy Cedeno, Tuixent Escriba, Miriam Rosas-Umbert, Mariona Parera, Maria Casadella, Miriam Lopez, Francisco Perez, Bruna Oriol-Tordera, Marta Ruiz-Riol, Josep Coll, Felix Perez, Anne R. Leselbaum, Ian McGowan, Devi Sengupta, Edmund G. Wee, Tomas Hanke, Roger Paredes, Yovaninna Alarcon-Soto, Bonaventura Clotet, Marc Noguera-Julian, Christian Brander, Jose Molto, Beatriz Mothe, Angel Rivero
Summary: The HTI vaccines were able to induce strong, polyfunctional, and broad T-cell responses, but they did not prevent viral rebound. However, in some participants, these vaccines were associated with a longer time off antiretroviral treatment, suggesting that their immunogenicity may be beneficial for future cure approaches.
Letter
Allergy
Florian Stehlin, Francesco Tommasini, Veronique Monzambani-Banderet, Cedric Girard, Daniel Yerly, Camillo Ribi, Yannick D. Muller
ALLERGOLOGY INTERNATIONAL
(2023)
Article
Multidisciplinary Sciences
Erola Ainsua-Enrich, Nuria Pedreno-Lopez, Carmen Bracke, Carlos Avila-Nieto, Maria Luisa Rodriguez de la Concepcion, Edwards Pradenas, Benjamin Trinite, Silvia Marfil, Cristina Miranda, Sandra Gonzalez, Ruth Toledo, Marta Font, Susana Benet, Tuixent Escriba, Esther Jimenez-Moyano, Ruth Pena, Samandhy Cedeno, Julia G. Prado, Beatriz Mothe, Christian Brander, Nuria Izquierdo-Useros, Julia Vergara-Alert, Joaquim Segales, Marta Massanella, Rosa Maria Benitez, Alba Romero, Daniel Molina-Morant, Julia Blanco, Bonaventur Clotet, Lourdes Mateu, Maria Luisa Pedro-Botet, Jorge Carrillo
Summary: Mass vaccination campaigns have been effective in reducing COVID-19 transmission and severity. However, the immune responses developed in patients with predominantly antibody-deficiencies (PAD) after vaccination vary. Different PAD patients show different levels of response to the vaccine, highlighting the need for immunomonitoring and personalized therapeutic strategies.
Article
Virology
Clara Duran-Castells, Anuska Llano, Ai Kawana-Tachikawa, Anna Prats, Ignacio Martinez-Zalacain, Mie Kobayashi-Ishihara, Bruna Oriol-Tordera, Ruth Pena, Cristina Galvez, Sandra Silva-Arrieta, Bonaventura Clotet, Eva Riveira-Munoz, Esther Ballana, Julia. G. Prado, Javier Martinez-Picado, Jorge Sanchez, Beatriz Mothe, Dennis Hartigan-O'Connor, Tony Wyss-Coray, Andreas Meyerhans, Magnus Gisslen, Richard. W. Price, Carles Soriano-Mas, Jose Antonio Munoz-Moreno, Christian Brander, Marta Ruiz-Riol
Summary: High levels of SIRT2 are associated with uncontrolled HIV infection, plasma viral load, and proviral levels. SIRT2 levels are also linked to markers of neurological damage and brain involution, especially in individuals who initiate cART later. Inhibition of SIRT2 could potentially be a therapeutic target for HIV infections and their associated neurological dysfunction.
JOURNAL OF VIROLOGY
(2023)
Article
Immunology
Luis Romero-Martin, Clara Duran-Castells, Mireia Olivella, Miriam Rosas-Umbert, Marta Ruiz-Riol, Jorge Sanchez, Dennis Hartigan-O'Connor, Beatriz Mothe, Alex Olvera, Christian Brander
Summary: This study investigates the relationship between HLA-E expression and NK cell characteristics and functions. The findings suggest that increased HLA-E expression and changes in NK subpopulations are associated with chronic HIV infection. Uncontrolled HIV infection leads to dysfunction of NK cells, loss of HLA-E regulation, and reduced viral control. The study also demonstrates the potential sensitivity of target cells presenting HIV-derived epitopes to NK lysis. However, prolonged exposure to elevated HLA-E expression levels may result in NK cell dysfunction and reduced viral control in chronic infection.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Alessandra Borgognone, Aleix Elizalde-Torrent, Maria Casadella, Luis Romero, Tuixent Escriba, Mariona Parera, Francesc Catala-Moll, Marc Noguera-Julian, Christian Brander, Alex Olvera, Roger Paredes
Summary: The gut microbiota plays a crucial role in vaccine responses, and this study found that T-cell vaccination can alter the gut microbiota and promote the growth of bacteria that produce anti-inflammatory molecules. These changes in the microbiota are associated with immune responses and pro-inflammatory cytokines.
NPJ BIOFILMS AND MICROBIOMES
(2022)
Biographical-Item
Allergy
Arthur Helbling, Oliver Hausmann, Marek Jutel, Cezmi A. Akdis, Werner J. Pichler
Review
Allergy
Werner J. Pichler, Lester Thoo, Daniel Yerly
Summary: Eosinophilia is a common manifestation in drug hypersensitivity reactions, and its cause is unclear. However, it seems to be related to off-target activities of drugs with immune receptors, resulting in T-cell stimulation and excessive IL-5 production. This IL-5-TCR signalosome hypothesis may explain eosinophilia in various circumstances and provide new therapeutic options for eosinophilic diseases.
Article
Allergy
Florian Stehlin, Rima Mahdi-Aljedani, Loris Canton, Veronique Monzambani-Banderet, Alix Miauton, Cedric Girard, Kevin Kammermann, Sylvain Meylan, Camillo Ribi, Thomas Harr, Daniel Yerly, Yannick D. Muller
FRONTIERS IN ALLERGY
(2022)
Article
Allergy
Natascha Wuillemin, Barbara Ballmer-Weber, Christoph Schlapbach, Lukas Jorg, Daniel Yerly
Summary: The study investigated the relationship between the reactivity pattern of drug-reacting T cells in drug allergic patients and their clinical manifestations. The results showed a shift from hapten pattern in mild allergic reactions to p-i pattern in severe life-threatening allergic reactions, indicating a need for reevaluation of preclinical risk assessment methods for new drugs.
FRONTIERS IN ALLERGY
(2022)
